Phenylbutazone , ≥98%(HPLC) , 50-33-9
Synonym(s):
4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione;Phenylbutazone
CAS NO.：50-33-9
Empirical Formula: C19H20N2O2
Molecular Weight: 308.37
MDL number: MFCD00005500
EINECS: 200-029-0
| Pack Size | Price | Stock | Quantity |
| 5G | RMB26.40 | In Stock |
|
| 25G | RMB49.60 | In Stock |
|
| 100G | RMB149.60 | In Stock |
|
| 500G | RMB493.60 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 106-108 °C (lit.) |
| Boiling point: | 448.76°C (rough estimate) |
| Density | 1.1591 (rough estimate) |
| refractive index | 1.6140 (estimate) |
| storage temp. | 2-8°C |
| solubility | Practically insoluble in water, sparingly soluble in alcohol. It dissolves in alkaline solutions. |
| form | Powder |
| pka | 4.5(at 25℃) |
| color | White to almost white |
| Water Solubility | <0.1 g/100 mL at 23.5 ºC |
| Merck | 14,7277 |
| BRN | 290080 |
| Stability: | Stable. Incompatible with strong oxidizing agents, strong acids, strong bases. |
| InChIKey | VYMDGNCVAMGZFE-UHFFFAOYSA-N |
| LogP | 3.160 |
| CAS DataBase Reference | 50-33-9(CAS DataBase Reference) |
| NIST Chemistry Reference | Phenylbutazone(50-33-9) |
| IARC | 3 (Vol. 13, Sup 7) 1987 |
| EPA Substance Registry System | Phenylbutazone (50-33-9) |
Description and Uses
Phenylbutazone, one of the earliest NSAIDs introduced, is now indicated for the symptomatic relief of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, gout, and acute superficial thrombophlebitis. The gastrointestinal and bone marrow toxicity observed in its early use have been greatly reduced by lower dosage (300 mg/d). Nevertheless, it is used primarily where other drugs have failed and then only for short-term therapy. The drug has a long serum half-life of about 100 h. It is a moderately active cyclooxygenase inhibitor and it suppresses both spontaneous and chemotactic motility of neutrophils. In addition to the serious gastrointestinal and hematological adverse effects, sodium and water retention, rash, vertigo, and dermatitis are observed.
A non-steroidal anti-inflammatory compound. An inhibitor of cyclooxygenase that is also a substrate for peroxidation by cyclooxygenase
Safety
| Symbol(GHS) |  GHS06 |
| Signal word | Danger |
| Hazard statements | H301-H312+H332-H315-H319-H335 |
| Precautionary statements | P261-P280-P301+P310-P302+P352+P312-P304+P340+P312-P305+P351+P338 |
| Hazard Codes | Xn,T,F |
| Risk Statements | 36/37/38-20/21/22-42/43-45-36-11 |
| Safety Statements | 36/37/39-26-45-22-53-36/37-16 |
| RIDADR | 3249 |
| WGK Germany | 3 |
| RTECS | UQ8225000 |
| TSCA | Yes |
| HazardClass | 6.1(b) |
| PackingGroup | III |
| HS Code | 29331990 |
| Hazardous Substances Data | 50-33-9(Hazardous Substances Data) |
| Toxicity | LD50 oral in rabbit: 781mg/kg |
